Daily Bulletin

Men's Weekly

.

Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis

MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix® and Gozellix® (kits for the preparation of gallium-68 (68Ga) gozetotide injection)...

Read more: Telix Doses First Patient in Phase 3 BiPASS Trial: PSMA-PET Imaging for Prostate Cancer Diagnosis

Business News

Workplace Health Checks: A Smart Investment for Small Business Success

Running a small business means every team member counts and when poor health leads to absenteeism or low energy, productivity and profits take a hit. Lost workdays, rising healthcare costs, and staff ...

Daily Bulletin - avatar Daily Bulletin

Rising Demand: Why Melbourne Needs More Electricians Now

Melbourne is running on change. Rooftops are filling with solar, carports are getting charge points, and older switchboards are being rebuilt so homes and shops can carry smarter, heavier loads. If yo...

Daily Bulletin - avatar Daily Bulletin

What Designers Really Think About Your Current Marketing Collateral

Key Takeaways: Designers notice structure, typography, and colour choices before the content itself Consistency across all collateral strengthens brand recognition and builds trust Overly bu...

Daily Bulletin - avatar Daily Bulletin

LayBy Deals